Tag: ESGCT
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Voyager Therapeutics, Inc. – Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis – – Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Biosciences strategic collaboration followed by $25 million payment triggered…
